We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

News   Aug 01, 2018 | Original story from the National Institute of Standards and Technology (NIST)

 
New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

HeLa cancer cells appear green wherever mouse monoclonal antibodies (mAb) have bound to tubulin, a structural protein important in cell division. Binding to tubulin and preventing cell growth is one way that mAb drugs could kill tumors—the type of research that may benefit from the use of NIST's monoclonal antibody reference material, NISTmAb. Credit: ©EnCor Biotechnology Inc.

 
 
 

RELATED ARTICLES

Immunotherapy Opportunities Lie in Glioma Molecular Landscape

News

A slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be vulnerable to immunotherapy, which gives the immune system a boost in fighting cancer.

READ MORE

Sprayable Gel Could Help the Body Fight Off Cancer After Surgery

News

Almost 95% of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a team has developed a spray gel embedded with immune-boosting drugs that could help.

READ MORE

Bacterial ‘Sleeper Cells’ Evade Antibiotics and Weaken Defence Against Infection

News

These bacteria persister cells stop replicating and can remain in this dormant, ‘sleeper-cell’ state for days, weeks or even months. When antibiotic treatment has been stopped, if some of these bacterial cells spring back to life, they can trigger another infection.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE